Exosomes致敏的树突状细胞在中晚期大肠癌的临床应用研究

目的评估Exosomes致敏的树突状细胞对中晚期大肠癌的临床疗效。方法105例中晚期大肠癌患者随机分为免疫联合化疗组（n=65）和单纯化疗组（n=50）,观察两组患者的外周血T淋巴细胞亚群含量、有效率、1年生存率、中位生存时间及毒副反应。结果治疗前两组T淋巴细胞亚群含量比较无显著性差异,免疫联合化疗组治疗后与治疗前比较,CD3^＋、CD4^＋及CD8^＋明显增高（P〈0.05）,且优于单纯化疗组（P〈0.05）;联合治疗组与单纯化疗组有效率分别为56.9%和38.0%（P〈0.05）,1年生存率分别为66.7%和52.1%（P〈0.05）,中位生存时间分别为15.6个月和12.3个月（P〈0.05）,两组毒副反应无统计学意义（P〉0.05）。结论Exosomes致敏的树突状细胞回输联合化疗对中晚期大肠癌有较好的疗效,可提高免疫功能,延长生存期。

Clinical application study of dendritic cells sensitized by Exosomes in the treatment of advanced colorectal cancer

Objective To evaluate the effect of dendritic cells（DC） sensitized by Exosomes in the treatment of advanced colorectal cancer. Methods One hundred and five patients with advanced colorectal cancer were ran- domly divided into combination treatment group （ chemotherapy ＋ DC sensitized by Exosomes ） （ n = 65） and chemotherapy group（ n = 50） for observation of the T cell subsets in peripheral blood, response rate, one year survival rate, median survival time and toxicity. Results CD3^＋ ,CD4^＋ and CD8^＋ in combination treatment group after treatment were improved（P 〈 0.05 ）, which was also superior to chemotherapy group （ P 〈 0.05 ）. Response rates were 56.9% in combination treatment group and 38.0% in chemotherapy group（P〈0.05）. One year survival rate and median survival time were 66.7 % and 15.6 months, respectively, in patients allocated to combination treatment group compared with 52.1% and 12.3 months, respectively, in patients allocated to chemotherapy group（ P〈 0.05 for both comparisons）. There was no significant difference in toxicity between both groups（ P 〉 0.05 ）. Conclusion Dendritic cells sensitized by Exosomes combined chemotherapy is well effective and tolerated in the treatment of advanced colorectal cancer, improve immunity function and prolong survival period.